ライフサイエンスコーパス: beta-synuclein

1 ession in the cortex of mice over-expressing beta-synuclein.

2 e-knockout (KO) mice that lack alpha- and/or beta-synuclein.

3 synuclein is redundant with the very similar beta-synuclein.

4 d in untransfected cells or cells expressing beta-synuclein.

5 calization, in particular between alpha- and beta-synuclein.

6 rogeny of these mice that also express human beta-synuclein, a homologue of alpha-synuclein, show sig

7 The levels of beta-synuclein, a possible negative regulator of alpha-s

8 leins regulate proteasomal function and that beta-synuclein acts as a negative regulator of alpha-syn

9 how sequence differences between alpha- and beta-synuclein affect individual microscopic processes i

10 otein 1 (VILIP-1), neuronal pentraxin 2, and beta-synuclein, along with positron emission tomography

11 in cells transfected with vector control or beta-synuclein, alpha-synuclein-transfected cells were r

12 Beta-synuclein also rapidly formed soluble oligomers and

13 In doubly transgenic mice, beta-synuclein ameliorated motor deficits, neurodegenera

14 on might involve direct interactions between beta-synuclein and Akt and suggest that this signaling p

15 In contrast, WT beta-synuclein and all four Tyr-to-Cys mutant beta-synuc

16 synuclein, alpha-synuclein deletion mutants, beta-synuclein and beta/alpha-synuclein chimeras was ass

17 ations that included increased expression of beta-synuclein and gamma synuclein.

18 the contribution of synuclein family members beta-synuclein and gamma-synuclein to DAT trafficking is

19 f two other members of the synuclein family, beta-synuclein and gamma-synuclein, in the development a

20 a-Synuclein has two close homologues, termed beta-synuclein and gamma-synuclein.

21 Here, we find that alpha-synuclein, beta-synuclein, and apolipoprotein A-1 have the conserve

22 SNAP-25, 14-3-3 zeta/delta, beta-synuclein, and neurogranin exhibited the highest di

23 Alpha-synuclein and its homologue beta-synuclein are both natively unfolded proteins that

24 alpha and beta-synuclein are homologous proteins found at comparab

25 Our results suggest that the role of beta-synuclein as a putative modulator of neuropathology

26 beta-synuclein (beta-syn) is a presynaptic protein, whos

27 imed to assess the prognostic value of serum beta-synuclein (beta-syn), neurofilament light chain (Nf

28 ifferent cellular environments could control beta-synuclein (betaS) aggregation via altering its char

29 d the LB variant of Alzheimer's disease, but beta-synuclein (betaS) and gamma-synuclein (gammaS) have

30 Further, beta-synuclein (betaS) and gamma-synuclein (gammaS) immu

31 The closely related homolog beta-synuclein (betaS) is essentially fibril-resistant u

32 beta-Synuclein (betaS), which co-localizes with alphaS,

33 egenerative pathologies [alpha-synuclein and beta-synuclein (betaS)], as well as in various types of

34 unmodified and phosphorylated forms of human beta-synuclein by fusing a recombinant protein thioester

35 ty and identified as a mixture of alpha- and beta-synucleins by microsequencing and Western blotting.

36 These results suggest that beta-synuclein can act as a natural inhibitor of alpha-s

37 Supporting the hypothesis that beta-synuclein can act as a neurodegeneration-inducing f

38 Recent findings have supported the view that beta-synuclein can act as an ameliorating regulator of a

39 nd efficient aggregation and fibrillation of beta-synuclein can be induced in the presence of a varie

40 Expression of beta-synuclein caused mitochondrial fragmentation, but t

41 mature cultured primary neurons, alpha- and beta-synuclein colocalized almost exclusively with synap

42 beta-synuclein colocalizes with alpha-synuclein in presy

43 PD, we demonstrated that over-expression of beta-synuclein could retard the progression of impaired

44 eta-synuclein and all four Tyr-to-Cys mutant beta-synucleins did not cause protein aggregation and ce

45 mal subunit S6', unlike alpha-synuclein, but beta-synuclein does bind alpha-synuclein and competes wi

46 Unlike alpha-synuclein, overexpressed beta-synuclein does not cause pathological changes in th

47 Unlike its homologue, beta-synuclein does not form fibrils and has been shown

48 ents demonstrated that recombinant monomeric beta-synuclein does not interact with the proteasomal su

49 essentially continuous helix, whereas aS and beta-synuclein encounter a distinct helix break, indicat

50 ence of these metals, mixtures of alpha- and beta-synucleins exhibited rapid fibrillation.

51 ures and showed that the onset of alpha- and beta-synuclein expression was delayed after synaptic dev

52 lein readily assembles into amyloid fibrils, beta-synuclein fails to do so.

53 Furthermore, beta-synuclein formed proteinase K-resistant aggregates

54 We have observed that the beta-synuclein gene (HGMW-approved symbol, SNCB) is high

55 determined the intron-exon structure of the beta-synuclein gene and established sequencing assays th

56 l facilitate the search for mutations in the beta-synuclein gene in patients with Parkinson disease o

57 Although beta-synuclein had no direct effect on proteasomal activ

58 mparable levels in presynaptic terminals but beta-synuclein has a greatly reduced propensity to aggre

59 oxic in transgenic mice, and fibrillation of beta-synuclein has been demonstrated in vitro.

60 Indeed, beta-synuclein has been reported to protect against alph

61 ng body of evidence that alpha-synuclein and beta-synuclein have opposite neuropathophysiological eff

62 beta-Synuclein, however, differs significantly from alph

63 Exogenous beta-synuclein improves the movement defects and prolong

64 Thus, aberrant accumulation of alpha- and beta-synuclein in degradative organelles are novel featu

65 Others have shown that alpha and beta-synucleins inhibit phospholipase D (PLD), an enzyme

66 Recombinantly expressed alpha- and beta-synucleins inhibit PLD2 activity in vitro (K0.5 10

67 Monomeric alpha- and beta-synucleins inhibited the 20 S and 26 S proteasomal

68 Significantly, beta-synuclein inhibits the generation of A53T alpha-syn

69 Decapeptides targeted at the alpha-/beta-synuclein interaction sites are rationally designed

70 No significant incorporation of beta-synuclein into the fibrils was detected.

71 Beta-synuclein is an emerging blood biomarker for detect

72 beta-synuclein is closely related to alpha-synuclein and

73 ased on the following observations: 1) human beta-synuclein is highly homologous to alpha-synuclein b

74 The lack of fibrils formed by beta-synuclein is most readily explained by the absence

75 ucing factor, we demonstrated that wild-type beta-synuclein is neurotoxic for cultured primary neuron

76 beta-Synuclein is widely expressed throughout the centra

77 the putative impact of its close homologue, beta-synuclein, is enigmatic.

78 found increased adult neurogenesis in alpha/beta-synuclein knock-out mice.

79 High serum beta-synuclein level is a promising biomarker for AD-rel

80 High serum beta-synuclein level was correlated with lower Mini-Ment

81 Serum beta-synuclein level was progressively increased in the

82 Serum beta-synuclein level was similar between FTLD and contro

83 immunoprecipitation mass-spectrometry serum beta-synuclein levels in an exploratory cohort of 80 pat

84 indicated by zinc transporter-3 (ZnT3)-- and beta-synuclein--LI, as well as by Timm staining, all of

85 However, a mutation of beta-synuclein linked to dementia with Lewy bodies rende

86 It has been shown that both alpha- and beta-synucleins may be able to inhibit phospholipase D2

87 Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for t

88 Our results raise the possibility that beta-synuclein might be a natural negative regulator of

89 d with alpha-synuclein accumulation and that beta-synuclein might protect the central nervous system

90 tis elegans strain, while disease-associated beta-synuclein mutants aggravate the symptoms.

91 of alpha-synuclein, while disease-associated beta-synuclein mutations lose these capacities.

92 hese results indicate that the mechanisms of beta-synuclein neuroprotection might involve direct inte

93 se B) signaling pathway in the mechanisms of beta-synuclein neuroprotection.

94 uggested that this may be due to the lack in beta-synuclein of a hydrophobic region that spans residu

95 The effects of beta-synuclein on the Akt pathway appear to be by direct

96 ons of these brains, none of which contained beta-synuclein or gamma-synuclein abnormalities.

97 Here, we report that beta-synuclein partitions into alpha-synuclein condensat

98 Membrane binding is also strong for beta-synuclein, phosphorylated alpha-synuclein, and a sy

99 The beta-synuclein protein is highly homologous to the alpha

100 ndings indicate that increased expression of beta-synuclein protein results in a reduction of alpha-s

101 rant translocation of presynaptic alpha- and beta-synuclein proteins to these organelles in the perik

102 Beta-synuclein protofibrils do not bind to or permeabili

103 own experiments suggested that antagonism by beta-synuclein resulted from binding to alpha-synuclein

104 ference for the interaction with 2N, whereas beta-synuclein showed preference for 0N.

105 In particular, we show that beta-synuclein strongly suppresses both lipid-induced ag

106 apoE, mitochondrial creatine kinase U-type, beta-synuclein, synaptogyrin-3, synaptophysin, syntaxin

107 )) induce a partially folded conformation of beta-synuclein that triggers rapid fibrillation.

108 We characterized beta-synuclein, the non-amyloidogenic homolog of alpha-s

109 icity in such bigenic mice to the ability of beta-synuclein to reduce alpha-synuclein protein express

110 binding are examined in reference to aS and beta-synuclein to study the sequence characteristics und

111 Beta-synuclein transfection resulted in increased Akt ac

112 We generated beta-synuclein transgenic mice and observed a marked red

113 unveil a Yin-Yang balance between alpha- and beta-synuclein underlying the normal and disease states

114 a-, beta-, and gamma-synuclein revealed that beta-synuclein was eventually as neurotoxic as alpha-syn

115 The metal-induced fibrillation of beta-synuclein was further accelerated by the addition o

116 We found that beta-synuclein was of intermediate toxicity to yeast, an

117 ection with a lentiviral vector encoding for beta-synuclein was protective.

118 beta-Synuclein was the most abundant message (75-80%), f

119 ed in cases of diffuse LBD (DLBD), levels of beta-synuclein were decreased in AD and DLBD, and levels

120 nsgenic mice expressing human (h) alpha- and beta-synuclein were generated.

121 Similarly, cell lines transfected with beta-synuclein were resistant to alpha-synuclein accumul

122 A similar pattern occurs for the homologue, beta-synuclein, which does not undergo pathogenic aggreg

123 beta-Synuclein, which lacks 11 central hydrophobic resid

124 beta-Synuclein, which shares 60% identity with alpha-syn

125 roteasomal activity, co-incubating monomeric beta-synuclein with aggregated alpha-synuclein antagoniz

126 Furthermore, a chimera of beta-synuclein with alpha-synuclein(73-83) inserted was

127 Co-incubating beta-synuclein with gamma-synuclein had no effect on the